CA2753236A1 - Pyrrolopyrimidines used as kinase inhibitors - Google Patents

Pyrrolopyrimidines used as kinase inhibitors Download PDF

Info

Publication number
CA2753236A1
CA2753236A1 CA2753236A CA2753236A CA2753236A1 CA 2753236 A1 CA2753236 A1 CA 2753236A1 CA 2753236 A CA2753236 A CA 2753236A CA 2753236 A CA2753236 A CA 2753236A CA 2753236 A1 CA2753236 A1 CA 2753236A1
Authority
CA
Canada
Prior art keywords
pyrrolo
pyrimidin
propyl
amide
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2753236A
Other languages
English (en)
French (fr)
Inventor
Edward Giles Mciver
Joane Hough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
Medical Research Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council Technology filed Critical Medical Research Council Technology
Publication of CA2753236A1 publication Critical patent/CA2753236A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2753236A 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors Abandoned CA2753236A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0903759.9A GB0903759D0 (en) 2009-03-04 2009-03-04 Compound
GB0903759.9 2009-03-04
US16203209P 2009-03-20 2009-03-20
US61/162,032 2009-03-20
PCT/GB2010/000394 WO2010100431A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2753236A1 true CA2753236A1 (en) 2010-09-10

Family

ID=40580647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2753236A Abandoned CA2753236A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors

Country Status (8)

Country Link
US (1) US20120088753A1 (enExample)
EP (1) EP2403853B1 (enExample)
JP (1) JP2012519678A (enExample)
CN (1) CN102341400A (enExample)
AU (1) AU2010219466A1 (enExample)
CA (1) CA2753236A1 (enExample)
GB (1) GB0903759D0 (enExample)
WO (1) WO2010100431A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
PL2714677T3 (pl) 2011-05-23 2019-02-28 Merck Patent Gmbh Pochodne pirydynowe i pirazynowe
CN103596938B (zh) 2011-05-23 2016-12-28 默克专利有限公司 噻唑衍生物
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
CN104093722B (zh) 2012-02-09 2016-07-27 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN106715419A (zh) 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
KR101660863B1 (ko) 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
KR101846475B1 (ko) 2015-04-27 2018-04-09 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
AU2016370916A1 (en) 2015-12-17 2018-06-07 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
WO2019156438A1 (en) 2018-02-07 2019-08-15 Korea Research Institute Of Chemical Technology Hetero ring-fused phenyl compounds for inhibiting tnik and medical uses thereof
CA3090233A1 (en) 2018-02-07 2019-08-15 Korea Research Institute Of Chemical Technology Compounds for inhibiting tnik and medical uses thereof
CN112225742B (zh) * 2020-12-11 2021-03-09 北京华氏开元医药科技有限公司 一种抑制vegfr活性的化合物、制备方法及应用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP2009506036A (ja) 2005-08-24 2009-02-12 レキシコン・ファーマシューティカルズ・インコーポレーテッド ピロロピリジン、ピロロピリミジンおよびピラゾロピリジン化合物、それらを含む組成物、ならびにそれらの使用方法
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها

Also Published As

Publication number Publication date
EP2403853A1 (en) 2012-01-11
WO2010100431A1 (en) 2010-09-10
GB0903759D0 (en) 2009-04-15
CN102341400A (zh) 2012-02-01
EP2403853B1 (en) 2013-08-14
US20120088753A1 (en) 2012-04-12
JP2012519678A (ja) 2012-08-30
AU2010219466A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
EP2403853B1 (en) Pyrrolopyrimidines used as kinase inhibitors
US9963462B2 (en) Sepiapterin reductase inhibitors
CN102007124B (zh) 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
US8362023B2 (en) Pyrazolo pyrimidines
US20100056524A1 (en) Compound
AU2009205501A1 (en) 3H-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their syntheses
KR20190018645A (ko) 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제
CA2542113A1 (en) Compositions useful as inhibitors of protein kinases
EP2086979A2 (en) Imidazoý1,2-b¨pyridazine and pyrazoloý1,5-a¨pyrimidine derivatives and their use as protein kinase inhibitors
AU2014307437A1 (en) Novel fused pyrimidine compound or salt thereof
AU2016355104B2 (en) Fused thiazolopyrimidine derivatives as MNKs inhibitors
WO2023224998A1 (en) Inhibitors of parg
CA3147422A1 (en) Inhibitors of cyclin-dependent kinases
CA2591125A1 (en) Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
US20240425501A1 (en) Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors
US11939335B2 (en) Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG
AU2016355103B2 (en) Pyrropyrimidine compounds as MNKs inhibitors
CA3173804A1 (en) Fused aza-heterocyclic amide compound and use thereof
AU2024231943A1 (en) Biarylamide derivatives and their use as pkmyt1 inhibitors
CN115843296B (zh) Cdk9抑制剂及其用途
WO2025151478A1 (en) Compounds and composition for targeting tp53-y220c mutants
US20210221820A1 (en) Compounds for the modulation of myc activity
Meniconi Heteroaryl derivatives as sepiapterin reductase inhibitors
WO2025111492A1 (en) Inhibitors of parg
CN121159575A (en) Amino-substituted heteroaromatic ring compound, preparation method and medical application thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150304